Pilot Phase. During the period of performance of the Joint Development Program (the “Pilot Phase”), the objective is to demonstrate the ability to manufacture Bio-BDO via the Bioprocess using cellulosic sugars generated from Biomass feedstocks via the PROESA™ Process Technology in the Pilot Plant Facility. The principal tasks in the Pilot Phase shall consist of those matters set forth in the Development Plan.
Pilot Phase. (a) During the Pilot Phase, the responsibility of the Parties for costs and expenses will be as set forth in Schedule 3.1(a). Without the approval of the JDC, neither Party will incur any capital expenditures in the performance of the Pilot Phase except as expressly set forth in the Development Plan.
(b) […***…]. The JDC will determine whether the technical and commercial key performance indexes (KPIs) for the Pilot Phase, as set forth in the Development Plan (the “Commercialization KPIs”) have been satisfied. The Pilot Phase will continue until the date that the principal tasks in the Development Plan (and any other tasks reasonably determined by Genomatica) have been completed, whether or not the Commercialization KPIs have been satisfied.
Pilot Phase. (1) Upon completion of the Analytical Phase Sandoz shall implement the Process in its facilities and Manufacture the Pilot Batches of the API, although not necessarily in compliance with the API Specifications, for the purpose of qualifying the Process. In accordance with the Technology Transfer Plan, the Pilot Phase shall run for a minimum of **) **, with the actual number of total ** to be agreed upon by Unigene and Sandoz based on the results of the Pilot Phase. The parties acknowledge that Sandoz’s ability to conduct the Pilot Phase in accordance with this timetable is dependent on timely delivery by Unigene in accordance with the Technology Transfer Plan of agreed-upon Process Transfer Information. The parties agree to use their commercially reasonable endeavors to ensure that the timeline for the Pilot Phase is met.
(2) If during the Pilot Phase the parties identify an unforeseeable technical problem, which prevents Sandoz from Manufacturing the Pilot Phase Batches, then the following procedure shall apply:
(a) Sandoz may request further reasonable technical assistance from Unigene and Unigene shall according to Clause 4(8)(a)provide technical assistance as reasonably deemed appropriate by Sandoz.
(b) Sandoz shall use its commercially reasonable endeavors to resolve the problem to both parties’ satisfaction and Unigene shall be entitled to have a representative present at the Sandoz site and to fully participate in solving such problem to ensure that this provision is satisfied.
(3) If the parties are unable to resolve the problem in the manner described in Clause 3(2)(b) and are not progressing to a mutually agreeable resolution of the problem within a minimum of **) weeks of identification thereof, then Sandoz may terminate this Agreement, in which case the parties’ obligations hereunder shall terminate, other than each party’s obligation of confidentiality and to return the other party’s Confidential Information.
(4) Subject to completion of the Pilot Phase, Sandoz will conduct the Demonstration Lot Campaign, and will deliver the Product produced therefrom to Novartis Pharma AG upon completion of such campaign. The parties agree that the Demonstration Lot Campaign means that Sandoz shall Manufacture (a) up to ** Engineering Batches of API and (b) ** cGMP Batches of API that meet the API Specifications, within the timeline stated in Clauses 9(1)(c) and 11(1). If during the Demonstration Lot Campaign the parties identify an unforeseeable technical p...
Pilot Phase. The MOET will select a range of five (5) pre-schools. VTF will allocate materials and run training for the teachers of these five kindergartens. The place for the training will be decided by MOET. At this stage, all documents designed by VTF will be considered as drafts and all the teachers including in the training will contribute to the finalisation of the document. VTF will print the final documents in sufficient quantity for stage 2. The pilot phase shall be finalised by January 2015.
Pilot Phase. The Pilot Phase will involve defined group/s of SEIU 521 represented workers/Supervisors and management teams, as determined in the Design Phase, implementing the proposed operational model/s for a set period of time. During the Pilot Phase there will be regular check-ins, which will include iterative fine tuning, gathering data, and recognizing best practices and lessons learned. The Pilot Phase will continue for up to one (1) year.
Pilot Phase. There were two phases of piloting. The first phase was carried out to assess whether the trauma films in the acquisition phase produced the conditioned fear response according to SCR amplitude and subjective ratings. Changes were then made to the protocol and the second piloting phase was completed to further assess whether the stimuli were producing the conditioned fear response and to assess the feasibility of the design. The pilot participants were recruited via email and were all staff or students at King’s College London. They all met inclusion criteria for the study and gave written informed consent. Four participants completed the first phase of piloting. 50% of these participants did not meet minimum response criteria for the conditioned SCR. The mean age of these participants was 27 (SD=1.73) and three of these participants were female and one was male. The intensive presentation phase was added to the protocol to attempt to produce a more consistent conditioned response. Nine participants (three per group) completed the second phase of piloting. The mean age of these participants was 27.5 (SD=2.69), eight participants were female and one was male. Eight participants (88%) showed a conditioned SCR above minimum criteria. All participants reported an increase in subjective ratings of distress to the CS+ after viewing the trauma films. The main aim of the piloting stage was to assess whether the stimuli produced the conditioned fear response at acquisition according to SCR and subjective distress ratings. SCR was inspected visually and 10 out of the 13 pilot participants had produced an SCR amplitude of greater than 0.02µs in response to the unreinforced CS+. Eight out of nine participants in the second phase acquired the conditioned fear response according to this criterion, which was after the addition of the intensive presentation phase. For the participants who also viewed the CS- following conditioning (n=6), there was a significant difference between subjective distress ratings to the CS+ (mean=56.67, SD=23.38) and the CS- (mean=0, SD=0) following
Pilot Phase. Objective
Pilot Phase. The Program will commence with a pilot phase ("Pilot Phase") for the deployment of the Cymedix Software with the Pilot Providers. The objective of the Pilot Phase is to establish an electronic communication link between the Pilot Providers and Kaiser or its designated Plan TPA, enabling Kaiser to evaluate the viability of the link and the functionality of the Cymedix Software. The applications available to Pilot Providers during the Pilot Phase shall be limited to the following Healthcare Transactions (collectively, "Pilot Transactions"):
(a) Claim Submissions;
(b) Claim Acknowledgements; and
(c) Eligibility Transactions to the extent included in the Implementation Plan.
Pilot Phase. Transaction Fees that would otherwise be payable by Kaiser for Healthcare Transactions executed by Plan Providers through the Cymedix Software ("Transaction Fees") will be waived by the Company during the Pilot Phase.
Pilot Phase. This Sub-Activity covers the pilot phase of the operations of the locks and the control system. It will entail the following tasks: • Implementation of the new expert control system (software and hardware solutions), • Pilot operation of lock xxxxxxxx together with beta version (testing environment) of the new expert control system.
